Disclaimer: This article is for informational purposes only and does not constitute personalised medical advice. Individuals with asthma should consult their healthcare provider for guidance specific to their condition.
When most people think of asthma, they picture a sudden wheeze triggered by pollen or exercise—a reversible narrowing of the airways that a rescue inhaler can fix. That picture is accurate for many, but it misses a quieter, more insidious process: airway remodelling. Over years of recurrent inflammation, the lungs of a person with persistent asthma can lose elasticity, stiffening in ways that a bronchodilator alone cannot reverse. A landmark study by Hogg and colleagues, published in the American Journal of Respiratory and Critical Care Medicine in 2004, quantified this loss: in a cohort of 23 adults with chronic asthma (mean disease duration 27 years) compared to 26 healthy controls, lung elasticity measured by pressure-volume curves was roughly 11 percent lower in the asthma group. This figure has since shaped how researchers think about the disease—not just as a condition of acute attacks, but as a progressive structural disorder.
The Stiffening Lung: A Hidden Consequence of Chronic Inflammation
Asthma has long been defined by its reversibility. The classic teaching is that airway obstruction comes and goes, and lung function returns to near-normal between exacerbations. But that narrative obscures a reality that pathologists have known for decades: the airways of people with persistent asthma are structurally altered. The bronchial walls thicken, the smooth muscle layer hypertrophies, and the subepithelial region becomes scarred with collagen. These changes are collectively called airway remodelling, and they accumulate with each flare-up.
The loss of elastic recoil is one of the most functionally important consequences of remodelling. Healthy lungs are like a balloon that snaps back after being inflated; in asthma, that balloon becomes stiffer. The elastic fibres that normally allow the lung to expand and contract are progressively fragmented and replaced by less compliant collagen. This shift reduces the lung's ability to expel air passively during exhalation, forcing the respiratory muscles to work harder.
The 11 percent figure from the Hogg study is not trivial. It represents a population-level average, and individual variation is wide, but the trend is consistent: longer disease duration correlates with greater stiffness. Importantly, this loss is not fully reversible with bronchodilators. Even after maximal pharmacological reversal of bronchospasm, the elasticity deficit remains, indicating that structural damage, not just smooth muscle contraction, is at play.
There are parallels with chronic obstructive pulmonary disease (COPD), where emphysema destroys alveolar walls and reduces elastic recoil in a different way. In COPD, the loss is due to tissue destruction; in asthma, it is due to fibrosis and thickening. Both lead to air trapping and difficulty exhaling, but the underlying mechanisms diverge, which matters for treatment. Asthma's remodelling is driven more by eosinophilic inflammation and T-helper 2 cytokines, while COPD involves neutrophilic inflammation and protease–antiprotease imbalance.
Mechanism at the Tissue Level: Matrix Metalloproteinases and Elastin Degradation
To understand why the lung stiffens, one has to look at the extracellular matrix—the scaffold of proteins that gives lung tissue its mechanical properties. The key players are elastin, which provides recoil, and collagen, which provides tensile strength. In the healthy lung, these are in balance. In asthmatic airways, that balance tips toward collagen deposition and elastin breakdown.
Matrix metalloproteinase-9 (MMP-9) is an enzyme that cleaves elastin fibres. In asthmatic airways, MMP-9 activity is elevated, particularly during exacerbations. Over time, this fragments the elastic network, reducing the lung's ability to snap back after inflation. At the same time, transforming growth factor-beta (TGF-beta), a cytokine released by eosinophils and epithelial cells, stimulates fibroblasts to lay down excess collagen in the subepithelial layer. This process is sometimes called subepithelial fibrosis, and it is visible on biopsy specimens as a thickened basement membrane.
Smooth muscle hypertrophy adds another layer of stiffness. The bronchial smooth muscle layer in asthma can double or triple in thickness due to both hyperplasia (increased cell number) and hypertrophy (increased cell size). This muscle is not just contractile; it also secretes extracellular matrix proteins, further contributing to airway wall thickening. Animal models, particularly ovalbumin-sensitised mice, have shown that these structural changes persist even after the acute inflammatory trigger is removed, confirming that remodelling can become self-perpetuating.
Human biopsy studies have corroborated these findings. Bronchial biopsies from patients with mild-to-moderate asthma show increased subepithelial collagen deposition compared to healthy controls, and the degree of fibrosis correlates with disease severity and duration. Some studies have also found that even patients with well-controlled asthma who have normal spirometry can show evidence of remodelling on biopsy, suggesting that the process begins early and may precede detectable functional decline.
The 11 Percent Figure: What the Study Actually Found
The widely cited 11 percent figure comes from a study by Hogg and colleagues that compared lung elasticity in 23 adults with chronic asthma to 26 healthy controls. All participants underwent pulmonary function testing, including pressure-volume curves to measure elastic recoil. The asthma group had a mean loss of elastic recoil of about 11 percent at total lung capacity, and the deficit was more pronounced in those with a longer history of the disease. The difference persisted after administration of a bronchodilator, ruling out reversible bronchospasm as the cause.
The study's strength lies in its direct physiological measurement. Instead of relying on surrogate markers like FEV1 (forced expiratory volume in one second), the researchers used the gold-standard method of plotting lung volume against transpulmonary pressure. The slope of this curve reflects lung compliance—the inverse of elasticity. A steeper slope means a more compliant (less elastic) lung. The asthma group showed a significantly steeper slope, indicating loss of elastic recoil.
The sample size was modest, and the asthma group was relatively severe, with a mean duration of disease of roughly 27 years. Whether the same magnitude of elasticity loss occurs in milder or shorter-duration asthma is less clear. Subsequent studies have confirmed that remodelling is present even in mild asthma, but the quantitative relationship with elasticity may differ. Some researchers argue that the 11 percent figure should be interpreted as a benchmark for long-standing disease rather than a universal constant.
Another limitation is that the study did not directly measure airway wall thickness or fibrosis. The elasticity loss inferred from pressure-volume curves could also reflect changes in the lung parenchyma (the gas-exchanging tissue) rather than the airways alone. However, subsequent imaging studies using high-resolution computed tomography (CT) have shown that airway wall thickening correlates with reduced lung function, supporting the idea that the structural changes are primarily in the conducting airways.
Clinical Consequences: Beyond Exacerbations
The functional impact of reduced elastic recoil extends beyond the occasional asthma attack. During exhalation, the lung normally relies on elastic recoil to push air out passively. When recoil is diminished, the patient must actively contract expiratory muscles to maintain flow, which is less efficient and leads to earlier fatigue. This is why many people with long-standing asthma report dyspnea on exertion that seems out of proportion to their FEV1—the spirometry reading might look decent, but the mechanics of breathing are compromised.
Air trapping is a direct consequence. Because the airways are stiffer and close prematurely during exhalation, air gets trapped behind them, increasing residual volume. This hyperinflation flattens the diaphragm, reducing its mechanical advantage and making inspiration harder. Over time, patients may develop a barrel-chested appearance similar to that seen in COPD, though usually less pronounced. The trapped air also impairs gas exchange, contributing to hypoxemia during exercise.
Small airway closure during tidal breathing is another problem. In healthy lungs, small airways remain open even at low lung volumes. In asthmatic lungs, the combination of wall thickening, mucus plugging, and reduced elastic traction from surrounding tissue causes these airways to close during normal exhalation. When they reopen on the next breath, it requires a greater inspiratory effort, perpetuating a cycle of work and fatigue. This is one reason why patients with asthma often have a sensation of chest tightness even when their peak flow is normal.
Longitudinally, the remodelling process contributes to an accelerated decline in lung function over decades. While most people lose FEV1 at a rate of about 20–30 mL per year after age 30, those with persistent asthma can lose 40–50 mL per year, especially if they have frequent exacerbations. This accelerated decline increases the risk of developing fixed airflow obstruction that resembles COPD, sometimes called the asthma–COPD overlap syndrome. Identifying and treating remodelling early could potentially slow this trajectory.
Spacer Misuse as a Modifiable Contributor to Poor Control
While the structural changes of remodelling are not directly reversible by inhalers, poor inhaler technique can worsen inflammation and accelerate the process. Spacers—holding chambers attached to metered-dose inhalers—are designed to improve drug delivery to the lungs by reducing the need for perfect hand–breath coordination. Yet up to 70 percent of patients use their inhaler incorrectly, according to some estimates. Common errors include not pausing after actuation, inhaling too rapidly, and failing to shake the canister before use.
When a spacer is used incorrectly, the medication may deposit in the mouth and throat instead of reaching the airways, reducing the anti-inflammatory effect and increasing the risk of side effects like oral thrush. Inhaled corticosteroids are the mainstay of asthma control; if they are not delivered effectively, inflammation persists, and remodelling progresses. Direct observation of technique in clinic can correct many of these errors, but time constraints often prevent thorough teaching.
Electronic monitoring devices are now available that record each actuation and provide feedback on timing and inhalation flow. Some studies have shown that these devices improve adherence and technique, leading to better asthma control and fewer exacerbations. While they add cost, they may be cost-effective in patients with frequent flare-ups. For clinicians, the takeaway is that remodelling is not just a biological inevitability; suboptimal medication delivery is a modifiable factor that, if addressed, could reduce the inflammatory burden that drives structural change.
A related issue is the underuse of spacers in emergency settings. During an acute exacerbation, a patient who normally uses a spacer may not have it available, leading to poor drug deposition and slower recovery. Hospitals and clinics should consider stocking spacers for acute use and training staff to teach patients on the spot. The small investment can have a large impact on short- and long-term outcomes.
Targeting Remodelling: Newer Biologics and Anti-Fibrotic Strategies
If remodelling is driven by inflammation, then better control of inflammation should slow or reverse it. This is the logic behind biologic therapies that target specific inflammatory pathways. Omalizumab, an anti-IgE antibody, has been shown in some CT studies to reduce airway wall thickness after one year of treatment, suggesting that it can partially reverse remodelling. Mepolizumab, which targets interleukin-5 (IL-5) and reduces eosinophil counts, has also been associated with improvements in airway structure, though the evidence is less robust.
More recently, drugs that directly inhibit fibrosis have been explored. Pirfenidone and nintedanib, both approved for idiopathic pulmonary fibrosis, have been studied in severe asthma models. Pirfenidone reduces TGF-beta signalling and collagen production; nintedanib inhibits tyrosine kinases involved in fibroblast activation. Early-phase trials have shown modest improvements in airway wall thickness on CT, but no large randomised controlled trials have yet demonstrated a clear clinical benefit in asthma. The challenge is that these drugs have significant side effects, including gastrointestinal intolerance and liver enzyme elevations, which may limit their use in a chronic condition like asthma.
Anti-IL-13 therapies, such as lebrikizumab and tralokinumab, have shown mixed results. IL-13 is a key driver of mucus production and subepithelial fibrosis. Some trials found a reduction in exacerbation rates and a modest improvement in FEV1, but others did not meet their primary endpoints. A meta-analysis suggested that the benefit is most pronounced in patients with high levels of serum periostin, a biomarker of IL-13 activity. This highlights the need for personalised approaches: not every patient will respond to the same anti-fibrotic strategy.
Early intervention may be the most effective strategy. Studies of children with asthma suggest that remodelling begins within the first few years of disease, and that early treatment with inhaled corticosteroids may prevent or delay structural changes. However, once fibrosis is established, it may be difficult to reverse. The window for preventing irreversible stiffness may be narrower than previously thought, which argues for aggressive controller therapy from the time of diagnosis, especially in children.
Takeaway for Clinicians: Measure What Matters
Standard spirometry—FEV1 and forced vital capacity (FVC)—is the backbone of asthma monitoring, but it is a blunt instrument. It reflects large airway function and is heavily effort-dependent. Small airway damage and lung stiffness can be present even when FEV1 is normal. Forced oscillation technique (FOT) is a newer method that measures respiratory impedance by superimposing small pressure oscillations on normal breathing. It can detect increased airway stiffness and small airway closure early, often before spirometry changes. Some guidelines now recommend FOT as an adjunct in specialist centres.
The lung clearance index (LCI), derived from multiple-breath washout tests, is another marker of ventilation heterogeneity. It is more sensitive than FEV1 for detecting small airway dysfunction and correlates with CT measures of air trapping. LCI is increasingly used in research and some paediatric clinics, though it requires specialised equipment and patient cooperation. For adults with symptom–spirometry mismatch—those who complain of dyspnea but have normal FEV1—FOT or LCI can provide objective evidence of impairment.
Routine CT or MRI is not justified for most asthma patients due to radiation exposure and cost, but it can be useful in selected cases where remodelling is suspected and other tests are equivocal. Research protocols increasingly use CT to quantify airway wall thickness and air trapping, and these measures correlate with symptom scores and exacerbation risk. As imaging techniques improve and radiation doses decrease, CT may become a more routine tool for phenotyping asthma.
Referral for impulse oscillometry (a variant of FOT) should be considered when there is a clear discordance between symptoms and spirometry. Many tertiary centres now offer this test, and it can guide decisions about escalating therapy or adding biologics. The goal is to move beyond a one-size-fits-all approach to asthma management and toward a phenotype-driven strategy that accounts for the structural as well as the functional aspects of the disease.
Future Directions: Open Questions in Remodelling Research
Several questions remain unanswered. First, can established fibrosis be reversed in humans? Animal studies suggest that some anti-fibrotic agents can reduce collagen content, but human data are scarce. Second, what is the optimal timing for initiating biologics to prevent remodelling? Current guidelines reserve biologics for severe asthma, but earlier use might preserve lung structure. Third, how do we identify patients at highest risk for rapid elasticity loss? Biomarkers such as serum MMP-9 or periostin may help, but they are not yet standardised. Finally, what role does ageing play in asthmatic lung stiffness? The interaction between age-related elastin degradation and asthma-related remodelling is poorly understood. Addressing these questions will require long-term studies with serial imaging and physiological measurements.
